Haemonetics (HAE) Stock Jumps 16% as CSL Plasma Commits to Full U.S. Equipment Deployment

Key Highlights

Table of Contents

Shares of Haemonetics jumped nearly 16% following CSL Plasma’s commitment to deploy NexSys devices nationwide.
The plasma collection giant aims to finish equipment installations at over 300 U.S. facilities by the end of 2027.
BTIG analysts lifted their price target to $130, while Citi previously upgraded the stock to Buy.
Recent quarterly results showed $339.38 million in revenue and diluted earnings of $0.72 per share.
Market participants anticipate November 5 earnings release for updates on CSL partnership revenue projections.

Shares of Haemonetics (HAE) climbed 15.96% on Thursday, October 8, 2026, reaching approximately $118 during morning hours from the prior close of $101.71. The rally followed CSL Plasma’s disclosure of plans to deploy the medical device company’s plasma collection technology throughout its entire U.S. footprint.

Haemonetics Corporation, HAE

CSL Plasma Commits to Comprehensive U.S. Deployment

CSL Plasma informed Haemonetics of its intention to install NexSys PCS devices equipped with Persona PLUS technology across every operational U.S. plasma donation center. The company established December 2027 as the completion target for this transition, affecting a network spanning more than 300 locations.

This commitment builds upon an August supply agreement granting CSL flexibility to purchase Haemonetics equipment without binding minimum order quantities. The arrangement permits CSL to source from other suppliers, and specific implementation schedules await final confirmation between the partners. Earlier in the week, European healthcare stocks gained, supported in part by positive clinical trial developments.

Wall Street Elevates Haemonetics (HAE) Price Projections

BTIG analysts increased their Haemonetics price objective from $110 to $130 on Thursday, maintaining their Buy recommendation. The previous month saw Citi shift its stance from Neutral to Buy, simultaneously raising its target from $92 to $123. These revisions arrived several weeks apart.

Citi’s analysis suggested that every 10% recovery in CSL-related business could contribute an additional $0.13 to annual earnings per share. Independent analyst estimates have placed potential annual sales from a complete CSL transition between $183 million and $223 million, though Haemonetics has issued no official guidance on these projections.

Latest Financial Performance and Vivasure Progress

The company’s June quarter delivered $339.38 million in total revenue alongside $0.72 in diluted earnings per share. Top-line growth measured 5.6% year-over-year. Free cash flow generation totaled approximately $39.1 million for the period. Meanwhile, U.S. stock indexes set records during the same week, though increasing bond yields created headwinds for select healthcare equities.

Haemonetics advanced its collaboration with Vivasure Medical through a $6.1 million milestone payment to Orchestra BioMed, bringing cumulative consideration to $11 million. The partnership structure allows for an additional $10 million in contingent payments tied to specific Vivasure revenue achievements.

Market Valuation and Upcoming Earnings Release

The medical device manufacturer holds roughly $1.17 billion in long-term debt and traded near 50 times trailing earnings during Thursday’s surge. This valuation multiple drew increased scrutiny following the day’s price advance. A recent retail investor survey revealed unusually elevated equity allocations across the broader market.

Haemonetics has maintained its fiscal 2027 outlook without revision, citing uncertainty around deployment timelines and order patterns. Management scheduled its second-quarter earnings announcement for November 5, when executives plan to provide clarity on anticipated revenue contributions from the expanded CSL relationship.